Loading stock data…
Lite Strategy (LITS)
$1.10-0.04 (-3.51%)
Market ClosedLast close Sep 8
Lite Strategy, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lite Strategy, Inc. in the Healthcare sector is trading at $1.10 with a market capitalization of $28M. The stock is currently near its 52-week low of $0.69, remaining 5.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 74 is overbought against a weak tape. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 74 against a weak tape — risk of pullback
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$2.77M↑ | -$3.35M↓ | -$3.11M↓ | -$2.88M↓ | -$2.77M |
| Net Income | -$23.69M↑ | -$30.80M↓ | -$3.64M↓ | -$2.69M↓ | -$2.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-107.01%
Volume
Today's trading volume
286,746
Recent News
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.
Can LitVM Bring Smart Contracts to Litecoin Without Changing Its Identity?
LitVM aims to bring smart contracts and DeFi capabilities to Litecoin without altering Litecoin's base-layer design as a simple payments network. Nasdaq-listed Lite Strategy ...
Exclusive: Lite Strategy leads $1m investment in Litecoin Layer 2 platform LitVM
Investing.com -- Lite Strategy, the first U.S. public company to hold Litecoin as its primary treasury reserve asset, will announce Thursday that it has closed a $1 million lead strategic investment in ZK Innovations Inc, Investing.com has learned.
Is Lite Strategy (NASDAQ:LITS) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...